Navigation Links
GeoPharma Announces Record Revenues in Third Quarter Results
Date:2/14/2008

5,853,929 3,742,952 13,400,893 11,011,141

Operating income (loss)

before other income and

expense, minority

interest, income taxes

and discontinued

operations $(2,278,474) $773,477 $(7,083,303) $1,676,915

Other income (expense),

net:

Other income (expense),

net 10,793 (410) 11,318 163,889

Interest income (expense),

net (240,311) (33,790) (313,277) (62,406)

Total other income

(expense), net $(229,518) $(34,200) $(301,959) $101,483

Income (loss) before

minority interest,

income taxes and

discontinued operations $(2,507,992) $739,277 $(7,385,262) $1,778,398

Minority interest benefit

(expense) 202,495 319,998 644,951 984,328

Income tax benefit

(expense) 729,951 (300,000) 2,415,353 (888,000)

Net income (loss) from

continuing operations $(1,575,546) $759,275 $(4,324,958) $1,874,726

Discontinued operations:

Revenues: PBM $-- $-- $2,925,139 $--

Cost of goods sold: PBM -- -- 2,904,274 --

Gross profit: PBM $-- $-- 20,865 $--

Selling, general and

administrative

expenses: PBM -- -- 20,785 --

PBM segment exit income

(expense) -- -- 8,300 --

Discontinued operations

net income (net of

income tax) $-- $-- $8,380 $--

Net income (loss) $(1,575,546) $759,275 $(4,316,578) $1,874,726

Preferred stock dividends 100,001 75,000 308,336 225,000

Net income (loss)

available to common

sha
'/>"/>

SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GeoPharma Announces Third Quarter Conference Call
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
7. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
8. VLST Corporation Announces Board and Executive Management Appointments
9. Advance Nanotech Announces Shareholder Proxy Vote Results
10. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
11. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...wire-FirstCall/ -- BioSpecifics Technologies Corp....eloping first-in-class collagenase-based products,...rd quarter ended September 30, 2009. ,, "We we..., the FDA,s Arthritis Advisory Committee unanimous... XIAFLEX(TM) for the treatment of Dupuytren,s dise...
(Date:11/6/2009)...ewswire-FirstCall/ -- ,, 3Q09 Corporate High... E.U. Marketing Authorization to Astellas Pharma E...al readiness activities Expanded management team ...nd Director, Commercial Operations Appointed Brad...mittee chairman , Upcoming 2009 Milestones:...
(Date:11/6/2009)... for Arrowhead’s 2010 Personalized Medicine ...e on February 22-24, 2010 in Philadelphia, has bee...highlight key issues in forming partnerships and e.... , Minneapolis, MN (PRWE...quo;s 2010 Personalized Medicine Partnerships Con...
(Date:11/5/2009)...wswire/ -- DSM Pharmaceutical Products today annou...h Galenix, Saint Jean D,Illac, France, where DSM w...g partner for Galenix commercial products on a glo...on business development opportunities co-marketing...strength of Galenix in drug product development an...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...ent of Accurate Blood Test for Common Genetic Diso...., Jan. 27 Artemis Health Inc., a privately-held ...ve prenatal diagnostic tests, today announced that...from Stanford University to develop cell-free fe...ing research from the lab of Stephen Quake, Ph.D.,...
...wswire-Asia/ -- Pharmaxis Ltd (AXS: PXS,Nasdaq: ...port to Shareholders,on the afternoon of Wednesday... an investor teleconference the following morning ...s. , The teleconference will be on Thursday, 2...nuary at 4:30pm U.S. East Coast, 1:30pm U.S. West ...
...tics (NYSE Alternext US: CXM) today reported that ...any,s Board of Directors. The resignation reduces..."We thank Dr. Simon for his service to the Board a...ed Christopher J. Reinhard, Chairman and Chief Exe...: http://www.newscom.com/cgi-bin/prnh/20051018/CA...
Other Biology Technology:Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 2Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 3Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4
(Date:11/4/2009)..., Nov. 4 GenVault Corporation (Car...., Ph.D., has joined its Board of Directors. Dr. ...Salk Institute, is an acclaimed physician-scientis...k Institute, Dr. Brody served as president of The ...ational Academy of Engineering and the Institute o...
(Date:11/3/2009)...be the ultimate loner of the ocean, cruising thous...searchers has discovered that the sharks have main... over tens of thousands of years the white sharks ...hemselves into a population genetically distinct f...ks are a large, highly mobile species," said Salva...
(Date:11/3/2009)...YETTE, Ind. - Chief executives in 35 of the top Fo...es their "ideal salaries" in 2008, according to a ...due University researcher to determine fair CEO co... and corporate governance issues of the day is how...nkat Venkatasubramanian, a professor of chemical e...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 2Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 1Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 4Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 5Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
... WHITE PLAINS, NY Babies born preterm were more t... full-term infants, according to a new analysis of...e this week in the Springer journal Maternal and C... before 37 completed weeks gestation, is a growing... Dimes. More than a half million babies are born t...
...own as neurons process information by joining into...her across junctions called synapses. But neurons ...Josh Huang, Ph.D., in a lot of cases, they connect... Dr. Huang, a professor at Cold Spring Harbor Lab...olecules guiding this highly specific neuronal tar...
...iologists from Austria and Singapore developed a t... between biology and art. In an article recently p...fasebj.org ) and scheduled for the August 2008 pri... able to coator paintviruses with proteins. This b... efficiency of some forms of gene therapy, help tr...
Other Biology News:Analysis of millions of US births shows association between birth defects and preterm birth 2Scientists discover a molecular scaffold that guides connections between brain cells 2Scientists discover a molecular scaffold that guides connections between brain cells 3Scientists 'paint' viruses to track their fate in the body 2
BMP-2 ELISA Kit from R&D Systems
5x MONO-RABBIT POLY C'GATE DILUENT from AbD Serotec
Argarase from BioVision
SAMPLE DILUENTS BUFFER TRIAL PACK from AbD Serotec
Biology Products: